<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264325</url>
  </required_header>
  <id_info>
    <org_study_id>7565</org_study_id>
    <nct_id>NCT04264325</nct_id>
  </id_info>
  <brief_title>Quantitative Diaphragmatic Ultrasound Evaluation in Pleural Effusions : A Feasability Study</brief_title>
  <acronym>ADD-Echo</acronym>
  <official_title>Quantitative Diaphragmatic Ultrasound Evaluation in Pleural Effusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural effusions cause breathlessness and impairs quality of life. Thoracocentesis
      is frequently used to relieve breathlessness.

      The severity of breathlessness correlates poorly with the size of the effusion. Symptom
      reduction from fluid drainage varies between patients. No predictors exist to identify which
      patients benefits more of pleural effusion. One study suggests that a inverted
      hemidiaphramatic (inverted shape) is associated with a greater dyspnea improvement. Others
      parameters of diaphragmatic motion have not been studied till now.

      This study aims to evaluate the feasability of diaphragmatic ultrasound evaluation (shape by
      B-mode, quiet, deep inspiratory motion and sniff diaphragm motion by TM-mode) before and
      after pleural drainage.

      Primary end point aims to evaluate the feasability of deep breath inspiratory excursion in
      ipsilateral side of thoracocentesis by anterior subcostal approach in the mid-clavicular line
      in the right in patients with malignant pleural effusions. The liver or spleen was identified
      as a window for each hemidiaphragm.

      Secondary end points aim to evaluate

        -  the feasability of quiet breath inspiratory motion ,

        -  the feasability of sniff diaphragm motion

        -  the feasability of deep breath inspiratory motion by posterior method

        -  the comparaison of feasibility with different types of breathing and or anterior or
           posterior approach for ultrasound

        -  the feasability of the shape by B-mode.

        -  the correlation between the change of the shape of ipsilateral diaphragm and the
           evolution of dyspnea, before and after thoracocentesis.

        -  the correlation between the volume of pleural effusion evacuated and the evolution of
           dyspnea, before and after thoracocentesis.

        -  the comparaison of the changing of dyspnea in patients with noticed paradoxal movement
           of diaphragm before thoracocentesis and patients with persistent paradoxal/or non
           persistant paradoxal movement of ipsilateral hémidiaphragm.

        -  the correlation between the feasability of diaphragmatic ultrasound motion measurments
           evaluation and the body mass index.

        -  the comparaison between the different diaphragmatic ultrsound times for anterior or
           posterior approach.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the feasibility of measuring the diaphragmatic amplitude in wide breathing (RA) on the side homolateral to the pleural puncture</measure>
    <time_frame>one day</time_frame>
    <description>Rate of patients with a feasible measure of diaphragmatic amplitude in wide breathing (RA), on the side homolateral to the pleural puncture, by the anterior route before and after pleural puncture.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasability of quiet breath inspiratory motion</measure>
    <time_frame>one day</time_frame>
    <description>Rate of patients with a feasible measure of diaphragmatic amplitude in spontaneous breathing (RS), on the side homolateral to the pleural puncture, by the anterior route before and after pleural puncture.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Malignant Pleural Effusion</condition>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Malignant pleural effusions : diaphragmatic ultrasound measure</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diaphragmatic ultrasound measure</intervention_name>
    <description>patients with lung neoplasms and malignant pleural effusions who need a diagnostic or therapeutic thoracocentesis</description>
    <arm_group_label>Malignant pleural effusions : diaphragmatic ultrasound measure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        30 patients with lung neoplasms and malignant pleural effusions who need a diagnostic or
        therapeutic thoracocentesis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18 years old

          -  Male or female patient

          -  Patient with known lung cancer, regardless of histology or suspected of having unknown
             lung cancer or relapse / progression of lung cancer

          -  Presenting a pleural effusion with clinical necessity of evacuating pleural puncture

          -  Subject who expressed his non opposition to the research

        Exclusion Criteria:

          -  Patient's refusal to participate in the study

          -  History of pleurodesis whatever the indication (pneumothorax or recurrent pleural
             effusion) or the technique used

          -  Permanent chest drain

          -  inability to provide informed information to the subject (subject in an emergency,
             difficulty understanding the subject, etc.)

          -  Subject under judicial protection

          -  Subject under guardianship or curatorship

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mickaël OHANA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mickaël OHANA</last_name>
    <phone>+33 3 69 55 11 17</phone>
    <email>mickael.ohana@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mickaël OHANA</last_name>
      <phone>+33 3 69 55 11 17</phone>
      <email>mickael.ohana@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Mickaël OHANA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth QUOIX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyspnea</keyword>
  <keyword>Malignant pleural effusion</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Therapeutic thoracocentesis</keyword>
  <keyword>Lung ultrasound</keyword>
  <keyword>Diaphragmatic ultrasound</keyword>
  <keyword>Diaphragmatic dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

